Abstract 11P
Background
Adjuvant treatment has become more personalized in resectable NSCLC. New biomarkers are needed to predict treatment outcomes. In this study, we looked for a broadly applicable biomarker using deep learning on hematoxylin and eosin (H&E) histology. Based on recommendations [Salgado et al., Ann Oncol 2015], we focused on analyzing tumor infiltrating lymphocytes in the stromal (sTILs) and the intratumoral (iTILs) compartment. We assessed TILs fully automated at slide and tumor bulk level, guided by manual annotations of the tumor bulk. We hypothesized high iTIL and sTIL density being associated with improved disease-free survival (DFS) in the total study population.
Methods
In this retrospective cohort study, 106 chemo-naive patients with resectable NSCLC were identified in two cohorts, based on recurrence (n=45, cohort A) versus no recurrence (n=61, cohort B). Whole mount tumor slides were stained with H&E and digitalized. Deep learning models were used to compute tissue masks [J. Spronck et al., PLMR 2023] and for TIL detection [HoverNet, Med Imag Anal. 2019]. Tumor bulk was manually annotated to exclude distant tumor lets. Distribution of iTIL and sTIL densities in cohort A and B were compared using Mann-Whitney U based on absence of normal distribution patterns. DFS was measured by log-rank and cox regression to correct for covariates after a binary distinction based on median TIL densities.
Results
The slide and annotation iTIL density were significantly higher in cohort B versus cohort A (slide: 300 vs 232 TILs/mm2, p=0.007 and annotation: 318 vs 230 TILs/mm2, p=0.013). The slide and annotation sTIL density were also higher in cohort B versus A (slide: 1489 vs 1153 TILs/mm2, p=0.035 and annotation: 1753 vs 1469, p=0.030). DFS was significantly higher in patients with a high slide iTIL density compared to patients with a low slide iTIL density (HR 0.44; 95% CI 0.24 to 0.81; P<0.009). DFS remained significant after correction for age, gender, smoking history co-morbidity and clinical stage, but not for ECOG performance.
Conclusions
The iTIL density detected on slide level could serve as favorable prognostic factor in patients with resectable NSCLC, potentially being a biomarker for adjuvant treatment.
Legal entity responsible for the study
The authors.
Funding
NWO/VIDI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract